Clinical Stage Stocks
Biopharmaceutical and medical technology firms in this segment operate without commercialized products, focusing instead on advancing therapeutic candidates through human clinical trials to secure regulatory approval. Revenue models are characterized by high cash burn rates and a total reliance on external financing or milestone-based partnerships rather than product sales.
As of Oct 23, 2026, Clinical Stage has 452 US-listed companies worth $546B combined. The median member moved +1.3% over the past week; MANE led among the 25 largest at +27.5% and IBRX trailed at -10.5%.
Companies in Clinical Stage
- NTRA – Natera Inc, $57.9B
- IQV – IQVIA Holdings Inc, $45.8B
- RVMD – Revolution Medicines Inc, $40.2B
- LH – Laboratory Corporation of America Holdings, $26.7B
- INSM – Insmed Inc, $20.4B
- MEDP – Medpace Holdings Inc, $18.3B
- ICLR – ICON PLC, $14.3B
- SMMT – Summit Therapeutics PLC, $12.3B
- PCVX – Vaxcyte Inc, $9.9B
- KYMR – Kymera Therapeutics Inc, $9.3B
- PTGX – Protagonist Therapeutics Inc, $9B
- IBRX – Immunitybio Inc, $8.8B
- SYRE – Spyre Therapeutics Inc., $8.7B
- ABVX – Abivax SA American Depositary Shares, $7.7B
- PRAX – Praxis Precision Medicines Inc, $7.2B
- MANE – Veradermics, Incorporated, $5.8B
- COGT – Cogent Biosciences Inc, $5.5B
- KOD – Kodiak Sciences Inc, $5.4B
- CGON – CG Oncology, Inc. Common stock, $5.3B
- ORKA – Oruka Therapeutics, Inc., $5.2B
- SRRK – Scholar Rock Holding Corp, $5.1B
- ERAS – Erasca Inc, $5.1B
- TVTX – Travere Therapeutics Inc, $4.9B
- BLLN – BillionToOne, Inc. Class A Common Stock, $4.8B
- TNGX – Tango Therapeutics Inc, $4.5B
- DFTX – Definium Therapeutics, Inc., $4.4B
- EWTX – Edgewise Therapeutics Inc, $4.3B
- DNTH – Dianthus Therapeutics Inc., $4.3B
- RLAY – Relay Therapeutics Inc, $4B
- VCYT – Veracyte Inc, $3.7B
- PLSE – Pulse Biosciences Inc, $3.7B
- AMLX – Amylyx Pharmaceuticals Inc, $3.6B
- XENE – Xenon Pharmaceuticals Inc, $3.5B
- IDYA – Ideaya Biosciences Inc, $3.5B
- VKTX – Viking Therapeutics Inc, $3.3B
- CELC – Celcuity LLC, $3.2B
- PBLS – Parabilis Medicines, Inc. Common Stock, $3.1B
- IRON – Disc Medicine Inc., $3B
- DNLI – Denali Therapeutics Inc, $3B
- DYN – Dyne Therapeutics Inc, $2.9B
- NRIX – Nurix Therapeutics Inc, $2.9B
- RCUS – Arcus Biosciences Inc, $2.8B
- BEAM – Beam Therapeutics Inc, $2.5B
- MBX – MBX Biosciences, Inc. Common Stock, $2.5B
- NAMS – NewAmsterdam Pharma Company N.V. Ordinary Shares, $2.4B
- CLDX – Celldex Therapeutics Inc, $2.3B
- SLS – Sellas Life Sciences Group Inc, $2.3B
- VERA – Vera Therapeutics Inc, $2.2B
- FTRE – Fortrea Holdings Inc., $2.1B
- NEO – NeoGenomics Inc, $2.1B
- PHVS – Pharvaris BV, $2.1B
- IMNM – Immunome Inc, $2.1B
- ZYME – Zymeworks Inc. Common Stock, $1.9B
- MLYS – Mineralys Therapeutics, Inc. Common Stock, $1.9B
- BRVE – Braveheart Bio, Inc. Common Stock, $1.9B
- XNCR – Xencor Inc, $1.9B
- ZBIO – Zenas BioPharma, Inc. Common Stock, $1.8B
- BHVN – Biohaven Ltd., $1.8B
- NVCR – Novocure Ltd, $1.8B
- PVLA – Palvella Therapeutics, Inc, $1.7B
- KLRA – Kailera Therapeutics, Inc. Common Stock, $1.7B
- COAG – Hemab Therapeutics Holdings, Inc. Common Stock, $1.7B
- NBTX – Nanobiotix, $1.7B
- STOK – Stoke Therapeutics Inc, $1.7B
- GPCR – Structure Therapeutics Inc. American Depositary Shares, $1.6B
- NTLA – Intellia Therapeutics Inc, $1.6B
- QURE – Uniqure NV, $1.6B
- CMPS – Compass Pathways Plc, $1.6B
- KRSA – Korsana Biosciences, Inc., $1.5B
- ANAB – AnaptysBio Inc, $1.5B
- MAZE – Maze Therapeutics, Inc. Common Stock, $1.5B
- TYRA – Tyra Biosciences Inc, $1.5B
- INBX – Inhibrx Biosciences, Inc., $1.4B
- TSHA – Taysha Gene Therapies Inc, $1.4B
- AAPG – Ascentage Pharma Group International, $1.4B
- RAPP – Rapport Therapeutics, Inc. Common Stock, $1.3B
- GHRS – GH Research PLC, $1.3B
- DRTS – Alpha Tau Medical Ltd, $1.3B
- REPL – Replimune Group Inc, $1.3B
- ORIC – Oric Pharmaceuticals Inc, $1.2B
- NKTR – Nektar Therapeutics, $1.2B
- TRAX – First Tracks Biotherapeutics, $1.2B
- KARD – Kardigan, Inc. Common Stock, $1.2B
- LBRX – LB Pharmaceuticals Inc Common Stock, $1.2B
- VOR – Vor Biopharma Inc, $1.2B
- BCAX – Bicara Therapeutics Inc. Common Stock, $1.2B
- LTGO – Latigo Biotherapeutics, Inc. Common Stock, $1.1B
- IMTX – Immatics NV, $1B
- SVRA – Savara Inc, $1B
- ANL – Adlai Nortye Ltd. American Depositary Shares, $999M
- SPTX – Seaport Therapeutics, Inc. Common Stock, $986M
- CGEM – Cullinan Oncology LLC, $961M
- ANRO – Alto Neuroscience, Inc., $956M
- MGTX – MeiraGTx Holdings PLC, $955M
- AKTS – Aktis Oncology, Inc. Common stock, $890M
- CBLL – CeriBell, Inc, $888M
- ALMS – Alumis Inc, $885M
- ODTX – Odyssey Therapeutics, Inc. Common Stock, $871M
- JBIO – Jade Biosciences, Inc., $853M
- GLUE – Monte Rosa Therapeutics Inc, $839M
- SANA – Sana Biotechnology Inc, $835M
- AVBP – ArriVent BioPharma, Inc. Common Stock, $821M
- MLTX – MoonLake Immunotherapeutics, $813M
- IMMX – Immix Biopharma Inc, $803M
- HELP – Cybin Inc., $799M
- SGP – SpyGlass Pharma, Inc., $792M
- APMD – Apnimed, Inc. Common Stock, $771M
- WVE – Wave Life Sciences Ltd, $745M
- OBX – Obsidian Therapeutics, Inc. Common Stock, $741M
- FTH – Faeth Therapeutics, Inc., $733M
- DSGN – Design Therapeutics Inc, $732M
- ACHV – Achieve Life Sciences Inc, $729M
- AVTX – Avalo Therapeutics Inc, $728M
- FDMT – 4D Molecular Therapeutics Inc, $711M
- CADL – Candel Therapeutics Inc, $709M
- PRME – Prime Medicine, Inc. Common Stock, $707M
- PROK – ProKidney Corp., $695M
- OLMA – Olema Pharmaceuticals Inc, $684M
- DBVT – DBV Technologies, $663M
- ABUS – Arbutus Biopharma Corp, $648M
- SGMT – Sagimet Biosciences Inc. Series A Common Stock, $633M
- ALT – Altimmune Inc, $595M
- CLYM – Climb Bio Inc, $592M
- CTMX – CytomX Therapeutics Inc, $556M
- ETRA – Electra Therapeutics, Inc. Common stock, $549M
- STTK – Shattuck Labs Inc, $548M
- CBIO – Crescent Biopharma, Inc., $532M
- VALN – Valneva SE ADR, $527M
- DRUG – Bright Minds Biosciences Inc, $506M
- ALLO – Allogene Therapeutics Inc, $504M
- EPRX – Eupraxia Pharmaceuticals Inc. Common Stock, $493M
- ACRS – Aclaris Therapeutics Inc, $483M
- AUTL – Autolus Therapeutics Ltd, $482M
- RGNX – Regenxbio Inc, $473M
- OCS – Oculis Holding AG Ordinary shares, $461M
- MPLT – MapLight Therapeutics, Inc. Common Stock, $458M
- BLSM – BlossomHill Therapeutics, Inc. Common Stock, $458M
- DMAC – DiaMedica Therapeutics Inc, $449M
- TECX – Tectonic Therapeutic, Inc., $444M
- PRTA – Prothena Corporation plc, $435M
- ENTX – Entera Bio Ltd, $435M
- NGNE – Neurogene Inc, $431M
- AGMB – AgomAb Therapeutics NV American Depositary Shares, $422M
- AVIR – Atea Pharmaceuticals Inc, $413M
- NAUT – Nautilus Biotechnology Inc, $412M
- ASMB – Assembly Biosciences Inc, $409M
- RZLT – Rezolute Inc, $396M
- KYTX – Kyverna Therapeutics, Inc. Common Stock, $395M
- CAPR – Capricor Therapeutics Inc, $384M
- TRXB – TRex Bio, Inc. Common stock, $384M
- SCTX – Scribe Therapeutics Inc. Common Stock, $380M
- INDP – Indaptus Therapeutics Inc, $380M
- GALT – Galectin Therapeutics Inc, $374M
- OBIO – Orchestra BioMed Holdings Inc., $358M
- ENTA – Enanta Pharmaceuticals Inc, $352M
- TTRX – Turn Therapeutics Inc. Common Stock, $337M
- ARTV – Artiva Biotherapeutics, Inc. Common Stock, $332M
- IRD – Opus Genetics, Inc., $318M
- FULC – Fulcrum Therapeutics Inc, $279M
- SRZN – Surrozen Inc, $276M
- AGEN – Agenus Inc, $273M
- CTNM – Contineum Therapeutics, Inc. Class A Common Stock, $266M
- BBOT – BridgeBio Oncology Therapeutics, Inc., $265M
- OCGN – Ocugen Inc, $265M
- SABS – SAB Biotherapeutics Inc, $262M
- PRLD – Prelude Therapeutics Inc, $258M
- IMRX – Immuneering Corp, $255M
- LCTX – Lineage Cell Therapeutics Inc, $251M
- IKT – Inhibikase Therapeutics Inc, $251M
- PALI – Palisade Bio Inc, $251M
- CABA – Cabaletta Bio Inc, $251M
- IPSC – Century Therapeutics Inc, $250M
- BCYC – Bicycle Therapeutics Ltd, $245M
- VCRE – Vicore Pharma Holding AB American Depositary Shares, $244M
- RCKT – Rocket Pharmaceuticals Inc, $239M
- QTTB – Q32 Bio Inc, $232M
- FATE – Fate Therapeutics Inc, $231M
- SLGL – Sol Gel Technologies Ltd, $227M
- GLSI – Greenwich Lifesciences Inc, $226M
- LRMR – Larimar Therapeutics Inc, $224M
- BIOA – BioAge Labs, Inc, $222M
- PYXS – Pyxis Oncology Inc, $220M
- CGEN – Compugen, $219M
- MGNX – MacroGenics Inc, $218M
- LXEO – Lexeo Therapeutics, Inc. Common Stock, $217M
- VOGX – Vogenx Inc Common Stock, $216M
- CAMP – CAMP4 THERAPEUTICS CORPORATION, $215M
- ALEC – Alector Inc, $214M
- NAGE – Niagen Bioscience, Inc., $214M
- LYEL – Lyell Immunopharma Inc, $213M
- TRDA – Entrada Therapeutics Inc, $209M
- PRQR – ProQR Therapeutics BV, $195M
- WHWK – Whitehawk Therapeutics, Inc., $194M
- ELDN – Eledon Pharmaceuticals Inc, $190M
- SION – Sionna Therapeutics, Inc. Common Stock, $187M
- YARW – Yarrow Bioscience Inc, $183M
- ALXO – Alx Oncology Holdings , $173M
- DTIL – Precision BioSciences Inc, $173M
- ORMP – Oramed Pharmaceuticals Inc, $171M
- ANTX – AN2 Therapeutics Inc, $166M
Showing the 200 largest of 452 members by market cap.